Clover Health's CEO Sold Company Shares Worth $1.7 Million. Here's What That Means for Investors.
Key Points
CEO Andrew Toy sold 313,476 shares of Common Stock for a transaction value of ~$1.67 million as of July 1, 2026.
This transaction represented 3.16% of Toy's direct holdings, reducing direct ownership to 9,609,825 shares.
All shares were sold directly, with no indirect or derivative participation.
Andrew Toy, Chief Executive Officer of Clover Health Investments (NASDAQ:CLOV), reported the direct sale of 313,476 shares of Common Stock on July 1, 2026, for a transaction value of ~$1.67 million according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 313,476 |
| Transaction value | $1.7 million |
| Post-transaction shares (direct) | 9,609,825 |
| Post-transaction value (direct ownership) | $51.8 million |
Transaction value based on SEC Form 4 reported price ($5.32); post-transaction value based on the July 1 closing price ($5.39).
Key questions
- How does this sale affect Toy's overall ownership in Clover Health Investments?
Direct holdings declined by 3.16%, with Toy retaining 9,609,825 shares of Class A Common Stock after the sale, and no indirect or derivative holdings reported. - Is there any impact on Toy's capacity for further open-market sales?
Following this transaction, Toy holds approximately 96.8% of his pre-sale direct position, indicating substantial remaining capacity; future open-market trades may continue to be driven by restricted stock unit (RSU) vesting and related tax events. - Does the transaction signal a change in sentiment or alignment with shareholders?
This sale was a non-discretionary "sell to cover" event tied to tax obligations, so it does not reflect a shift in executive sentiment or portfolio strategy; the CEO maintains a large direct equity stake.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $2.21 billion |
| Net income (TTM) | -$56.94 million |
| Employees | 570 |
| 1-year price change | 82.01% |
* 1-year performance calculated using July 1st, 2026 as the reference date.
Company snapshot
- Clover Health offers Medicare Advantage insurance plans, including both PPO and HMO products, supported by the proprietary Clover Assistant software platform.
- It generates revenue primarily through insurance premiums and risk-adjusted payments from government healthcare programs, leveraging data-driven technology to manage medical costs and improve care outcomes.
- The company targets individuals eligible for Medicare, focusing on seniors and beneficiaries seeking value-driven healthcare coverage in the United States.
Clover Health Investments operates at scale in the U.S. Medicare Advantage market, utilizing advanced analytics and its Clover Assistant platform to drive operational efficiency and member engagement.
The company’s technology-centric approach aims to deliver better health outcomes while managing costs, positioning it competitively within the healthcare plans sector. Its strategy centers on expanding its member base and deepening relationships with healthcare providers through data-driven insights.
What this transaction means for investors
Clover Health CEO Andrew Toy’s July 1 sale of company stock came just days after shares hit a multi-year high of $5.59 on June 29. Even so, his disposition is not a cause for investor concern.
The shares were sold to fulfill tax withholding obligations incurred in connection with the vesting of RSUs, making this a non-discretionary transaction. Moreover, his post-sale holdings of 9.6 million shares represents a significant equity stake in the company, indicating his interests align with that of shareholders.
Clover Health stock soared after the company won a court case that mandated Medicare upgrade its rating in the government program. This helps to unlock additional revenue.
In addition, Clover reported an impressive 51% year-over-year increase in Medicare Advantage memberships in the first quarter of 2026. The rise in members contributed to strong 62% year-over-year growth in Q1 revenue to $749.2 million.
The excellent start to 2026 led Clover Health management to forecast full-year sales between $2.8 billion and $2.9 billion, an outstanding jump up from 2025’s $1.9 billion.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.